<DOC>
	<DOC>NCT02276612</DOC>
	<brief_summary>This study will assess the safety, efficacy and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-infected virologically suppressed adolescents 12 to &lt; 18 years of age.</brief_summary>
	<brief_title>Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents</brief_title>
	<detailed_description />
	<criteria>Key Currently on a stable antiretroviral regimen for ≥ 6 consecutive months Weight ≥ 35 kg (77 lbs.) Plasma HIV1 RNA levels &lt; 50 copies/mL for ≥ 6 months CD4+ cell count &gt; 100 cells/μL No resistance to elvitegravir (EVG), emtricitabine (FTC), lamivudine (3TC) or tenofovir (TFV) Hepatic transaminases (AST and ALT) ≤ 5 x upper limit of normal (ULN) Key A new AIDSdefining condition diagnosed within the 30 days prior to Screening Evidence of active pulmonary or extrapulmonary tuberculosis disease within 3 months of screening Pregnant or lactating subjects Hepatitis B or Hepatitis C virus infection Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>